【www.zhangdahai.com--专题心得体会】
【摘要】 目的 探讨丹参酮ⅡA磺酸钠对早期糖尿病肾病(DN)患者血清转化生长因子β�1(TGF-β�1)和Ⅳ型胶原(CⅣ)水平的影响。方法 64 例早期DN患者随机分为两组,对照组(32例) 采用糖尿病常规治疗,治疗组(32例) 在常规治疗基础上加用丹参酮ⅡA磺酸钠,疗程均为1个月。采用 ELISA法测定两组患者治疗前后血清TGF -β�1、CⅣ 水平,同时观察尿白蛋白排泄率(UAER)的变化。结果 治疗组患者治疗后血清TGF -β�1、CⅣ水平明显下降(P0.05)。两组治疗后UAER均较治疗前降低,治疗组降低更明显(P0.05) . In both groups, The levels of UAER were significantly reduced after treatment than those before treatment (P2.。对照组男15例,女17例,年龄37～65岁,平均(55.4±11.9)岁,病程(8.52±3.97)年,体重指数为(24.3±4.2)kg/m2.。两组患者性别、年龄、病程、体重指数比较差异均无统计学意义(P>0.05)。
1.2 方法
1.2.1 治疗方法 2组患者常规饮食控制、适当锻炼、降血糖药物治疗,严格控制血糖(空腹0.05)。两组治疗后UAER均较治疗前降低,治疗组降低更明显(P0.05)。见表1。
表1
两组各项检测指标比较(x±s)
组别例数收缩压(mm Hg)舒张压(mm Hg)FPG(mmol/L)TC(mmol/L)TG(mmol/L)LDL-C(mmol/L)
治疗组
治疗前32112.32±15.6371.35±6.545.67±1.265.36±1.202.07±0.812.24±0.76
治疗后32110.46±13.2970.22±5.495.62±1.245.30±1.212.04±0.652.21±0.58
对照组
治疗前32114.03±14.5272.04±6.875.69±1.315.38±1.172.05±0.762.27±0.83
治疗后32113.71±12.8871.59±5.455.66±1.295.35±1.152.03±0.682.25±0.64
组别例数HDL-C(mmol/L)Scr(μmol/L)UAER(μg/min)TGF-β�1(μg/L)CⅣ(μg/L)
治疗组
治疗前321.10±0.2587.67±16.24154.78±61.3369.62±18.1682.49±16.33
治疗后321.13±0.3384.79±16.3879.44±35.18��*Δ�50.38±11.74��*Δ�49.75±13.27��*Δ�
对照组
治疗前321.09±0.2686.94±17.32150.16±66.2367.91±18.2281.67±17.42
治疗后321.11±0.3085.21±16.84124.72±53.39��**�66.36±17.4379.26±14.98
注:与同组治疗前比较, �*P [3] Chen S, Jim B, Ziyadeh FN. Diabetic nephropathy and transforming growth factor beta : transforming our view of glomerulosclerosis and fibrosis buildup. Semin Nephrol, 2003,23(2) : 532-543.
[4] 刘志红.糖尿病肾病.中华肾脏病杂志,2000,16(2):126.
[5] Chen S,Hong S W,CruzM C,eta1.The key role of the transforming growth factor-beta system in the pathogensis of diabetic nephrothy.Ren Fail,2001,23(4):471.
[6] Teicher BA.The transforming growth factor beta Proteins:discoveries and insights.Cancer Metasis Rev,2001,20(1):l33.
[7] Hori Y, Katoh T, Hirakata M, et al. Anti-latent TGF-beta binding protein-1 antibody or synthetic oligopeptides inhibit extracellular matrix expression induced by stretch in cultured rat mesangial cells. Kidney Int,1998,53 (6) :1616-1625.
[8] Anderson S,Rennke HG,Brenner BM,et al.Nifedipine versus fosinopril in unine phrectomized diabenic rats.Kidney Int,2002,41(4):891-897.
[9] 唐锦辉,占成业.丹参酮ⅡA对大鼠肾间质纤维化的抑制作用.内科急危重症杂志,2008,14(1):16-18.
[10] Kim SK, Jung KH, Lee BC. Protective effect of Tanshinone ⅡA on the early stage of experimental diabetic nephropathy. Biol Pharm Bull, 2009, 32(2):220-224.
